From the annual scientific session of the American College of Cardiology, Orlando
Warfarin, the reigning standard therapy for stroke prevention in atrial fibrillation, has long been viewed by the pharmaceutical industry as a big fat sitting duck: it’s a widely prescribed, cheap drug that’s just begging for replacement by one of a host of easier to [...]
Posts Tagged as ‘ACC’
March 30, 2009
The Beginning of the End for Warfarin?
March 30, 2009
The Reticent Dr. Ridker
From the annual scientific session of the American College of Cardiology in Orlando.
Sunday, March 29, was arguably the best day of Dr. Paul M. Ridker’s distinguished career.
The father and champion of the hsCRP hypothesis–the idea that blood levels of the inflammatory marker high-sensitivity C-reactive protein is an important and modifiable risk factor for cardiovascular diseases–was part [...]
March 28, 2009
Heart Failure Re-admissions Targeted by the ACC
From the 2009 annual scientific session of the American College of Cardiology in Orlando
The American College of Cardiology wants to cut by 20% the current rate of hospital re-admissions for patients with heart failure by 2012, said Dr. Jack Lewin, the College’s CEO.
The ACC is motivated by both a desire to help patients and the opportunity to [...]
